hydroxyindoleacetic acid has been researched along with Atherosclerotic Parkinsonism in 36 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 7.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 3.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "26 patients with a paranoid-hallucinatory syndrome were treated with a fixed daily dose of haloperidol." | 3.65 | Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol. ( Ackenheil, M; Eben, E; Hippius, H; Rüther, E; Schilkrut, R, 1976) |
| "Prodipin does not cause an alteration in metabolite concentration in cases of interrupted therapy (group 1), but leads, in the case of continued therapy, to a 1." | 2.64 | CSF-changes of HVA and 5-HIAA during intermittent and continuous Parkinson therapy with particular regard to prodipin application. ( Oppel, F; Schulze, G, 1978) |
| "We describe two sporadic cases of dystonia-parkinsonism at different stages of disease progression." | 1.28 | Consideration on two cases of dystonia-parkinsonism. ( Balottin, U; Borgatti, R; Lanzi, G; Zambrino, CA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (50.00) | 18.7374 |
| 1990's | 13 (36.11) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 2 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herbert, MK | 1 |
| Kuiperij, H | 1 |
| Bloem, BR | 1 |
| Verbeek, MM | 1 |
| Navailles, S | 1 |
| Benazzouz, A | 1 |
| Bioulac, B | 1 |
| Gross, C | 1 |
| De Deurwaerdère, P | 1 |
| Taylor, JL | 1 |
| Bishop, C | 1 |
| Walker, PD | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Falaschi, P | 1 |
| Baldassarre, M | 1 |
| D'Urso, R | 1 |
| Forchetti, C | 1 |
| Polleri, A | 1 |
| Vanderheyden, JE | 1 |
| Dekoninck, WJ | 1 |
| Lefèvre, A | 1 |
| Mendlewicz, J | 1 |
| Fornaguera, J | 1 |
| Schwarting, RK | 1 |
| Boix, F | 1 |
| Huston, JP | 1 |
| Wesemann, W | 1 |
| Grote, C | 1 |
| Clement, HW | 1 |
| Block, F | 1 |
| Sontag, KH | 1 |
| Altagracia, M | 1 |
| Rojas, P | 1 |
| Kravzov, J | 1 |
| Rios, C | 1 |
| Matsubara, K | 1 |
| Gonda, T | 1 |
| Sawada, H | 1 |
| Uezono, T | 1 |
| Kobayashi, Y | 1 |
| Kawamura, T | 1 |
| Ohtaki, K | 1 |
| Kimura, K | 1 |
| Akaike, A | 1 |
| Di Rocco, A | 1 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Yahr, MD | 1 |
| Cheng, FC | 1 |
| Ni, DR | 1 |
| Wu, MC | 1 |
| Kuo, JS | 1 |
| Chia, LG | 1 |
| Dethy, S | 1 |
| Laute, MA | 1 |
| Damhaut, P | 1 |
| Goldman, S | 1 |
| Ueda, S | 1 |
| Aikawa, M | 1 |
| Ishizuya-Oka, A | 1 |
| Yamaoka, S | 1 |
| Koibuchi, N | 1 |
| Yoshimoto, K | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Oppel, F | 1 |
| Schulze, G | 1 |
| Rüther, E | 2 |
| Schilkrut, R | 2 |
| Ackenheil, M | 2 |
| Eben, E | 2 |
| Hippius, H | 2 |
| Gerlach, J | 1 |
| Thorsen, K | 1 |
| Fog, R | 1 |
| Doudet, DJ | 1 |
| Aigner, TG | 1 |
| McLellan, CA | 1 |
| Cohen, RM | 1 |
| García Ruiz, PJ | 1 |
| Mena, MA | 1 |
| Peñafiel, N | 1 |
| De Yébenes, JG | 1 |
| Skirboll, S | 1 |
| Wang, J | 1 |
| Mefford, I | 1 |
| Hsiao, J | 1 |
| Bankiewicz, KS | 1 |
| Pezzoli, G | 1 |
| Ricciardi, S | 1 |
| Masotto, C | 1 |
| Mariani, CB | 1 |
| Carenzi, A | 1 |
| Rausch, WD | 1 |
| Schallauer, E | 1 |
| Chan, WW | 1 |
| Riederer, P | 1 |
| Weiser, M | 1 |
| Zambrino, CA | 1 |
| Balottin, U | 1 |
| Borgatti, R | 1 |
| Lanzi, G | 1 |
| Bradbury, AJ | 1 |
| Costall, B | 1 |
| Jenner, PG | 1 |
| Kelly, ME | 1 |
| Marsden, CD | 1 |
| Naylor, RJ | 1 |
| Kish, SJ | 1 |
| Chang, LJ | 1 |
| Mirchandani, L | 1 |
| Shannak, K | 1 |
| Hornykiewicz, O | 1 |
| Di Paolo, T | 1 |
| Bédard, P | 1 |
| Daigle, M | 1 |
| Boucher, R | 1 |
| Saito, T | 1 |
| Ishizawa, H | 1 |
| Tsuchiya, F | 1 |
| Ozawa, H | 1 |
| Takahata, N | 1 |
| Johannessen, JN | 1 |
| Savitt, JM | 1 |
| Markey, CJ | 1 |
| Bacon, JP | 1 |
| Weisz, A | 1 |
| Hanselman, DS | 1 |
| Markey, SP | 1 |
| Yamamoto, M | 1 |
| Ujike, H | 1 |
| Ogawa, N | 1 |
| Teelken, AW | 1 |
| van den Berg, GA | 1 |
| Muskiet, FA | 1 |
| Staal-Schreinemachers, AL | 1 |
| Wolthers, BG | 1 |
| Lakke, JP | 1 |
| Burns, RS | 1 |
| LeWitt, PA | 1 |
| Ebert, MH | 1 |
| Pakkenberg, H | 1 |
| Kopin, IJ | 1 |
| Russ, H | 1 |
| Henning, K | 1 |
| Eckhardt, H | 1 |
| Przuntek, H | 1 |
| Collins, MA | 1 |
| Neafsey, EJ | 1 |
| Portmann-Cristesco, EM | 1 |
| Boissier, JR | 1 |
| Chase, TN | 1 |
2 reviews available for hydroxyindoleacetic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
[Use of the probenecid test for the diagnosis and treatment of Parkinsonism. Review of the literature and personal experience (author's transl)].
Topics: Aged; Brain; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Middle Aged; Neu | 1980 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr | 1974 |
2 trials available for hydroxyindoleacetic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
CSF-changes of HVA and 5-HIAA during intermittent and continuous Parkinson therapy with particular regard to prodipin application.
Topics: Aged; Antiparkinson Agents; Clinical Trials as Topic; Female; Homovanillic Acid; Humans; Hydroxyindo | 1978 |
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine; Dibenzazepines; Haloperido | 1975 |
32 other studies available for hydroxyindoleacetic acid and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.
Topics: Aged; Cerebrovascular Disorders; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 2013 |
High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Extracellular Spac | 2010 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpu | 2005 |
A neuropharmacological and neuroendocrine study on idiopathic and chronic pharmacological Parkinsonism.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Circadian Rhythm; Homovanillic Acid; Humans; Hyd | 1980 |
Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Functi | 1993 |
Functional studies on monoaminergic transmitter release in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; A | 1993 |
Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Brain Chemistry; Corpus Striatum; | 1993 |
Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Brain; Carbolines; Cells, Cultured; Do | 1998 |
Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism.
Topics: 1-Naphthylamine; 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Antidepressive Agents, Second-Genera | 1998 |
Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 1998 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Ago | 1999 |
Age-related dopamine deficiency in the mesostriatal dopamine system of zitter mutant rats: regional fiber vulnerability in the striatum and the olfactory tubercle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Antibodies; Disease Models, Animal; Dopamine; Free R | 2000 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
Topics: Adult; Female; Hallucinations; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1976 |
Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
Topics: Adult; Aged; Brain Damage, Chronic; Depression; Female; Hallucinations; Haloperidol; Homovanillic Ac | 1976 |
Positron emission tomography with 18F-dopa: interpretation and biological correlates in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Cerebral Cortex; Corpus Striatum; | 1992 |
Cinnarizine-induced parkinsonism in primates.
Topics: Animals; Biogenic Monoamines; Cinnarizine; Disease Models, Animal; Dopamine; Haplorhini; Homovanilli | 1992 |
In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 1990 |
n-hexane induces parkinsonism in rodents.
Topics: Animals; Corpus Striatum; Dopamine; Hexanes; Hexanones; Homovanillic Acid; Hydroxyindoleacetic Acid; | 1990 |
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; C | 1990 |
Consideration on two cases of dystonia-parkinsonism.
Topics: Carbidopa; Child; Dystonia; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; M | 1991 |
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Female; Homov | 1985 |
Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.
Topics: Aged; Aspartic Acid; Basal Ganglia Diseases; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltrans | 1985 |
Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1986 |
Neurochemical findings in the cerebrospinal fluid of schizophrenic patients with tardive dyskinesia and neuroleptic-induced parkinsonism.
Topics: Adult; Aged; Antipsychotic Agents; Catecholamines; Dopamine; Dyskinesia, Drug-Induced; Epinephrine; | 1986 |
The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amines; Animals; Brain | 1987 |
Metoclopramide-induced parkinsonism.
Topics: Aged; Aged, 80 and over; Anorexia; Gastritis; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M | 1987 |
Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Dopamine; Droxidopa; Female; Homovanillic Acid | 1989 |
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Corpus Striatum; Dopamine; Female; Homovanillic | 1985 |
The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucle | 1985 |
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1985 |
[Dopamine release in the rat nigrostratum system after hydroxy-5 tryptophan administration].
Topics: 5-Hydroxytryptophan; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Humans; Hydroxyindoleaceti | 1974 |